RNA therapies improved quality-of-life scores in hereditary transthyretin amyloidosis
Randomized trial results favored treatment for neuropathy-related quality of life and neurological impairment, while safety differences remained uncertain.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Compared with placebo, RNA therapies improved scores for neuropathy-related quality of life and neurological impairment in people with hereditary transthyretin amyloidosis. The pooled trials did not detect statistically significant differences in adverse effects, serious adverse effects, or deaths. Those safety findings remain uncertain and do not establish equivalent safety or longer survival.
The abstract omits follow-up lengths and clinically meaningful score thresholds. It also gives no direct comparison estimates supporting its claim that one RNA therapy class outperforms another.
What researchers found
Change in neuropathy-related quality of life (Norfolk QoL-DN)
Between-group difference in change from baseline, RNA therapies versus placebo; negative values favor RNA therapy. Follow-up duration was not reported in the abstract.
What the negative score means
The negative estimate means the score change favored RNA therapy over placebo. This is a difference in questionnaire points; the abstract does not say how large a change patients would notice in daily life.
Other outcomes and safety
Modified body mass index was also better preserved with RNA therapies than with placebo. For adverse effects and mortality, confidence intervals spanned lower and higher risks, leaving important uncertainty about safety.
The original publication
Neurological efficacy and safety of RNA therapeutics in hereditary transthyretin amyloidosis: a systematic review and meta-analysis of randomized controlled trials.
Sajjad M, Ashraf R, Bhagwan R et al.
Ther Adv Cardiovasc Dis · 2025
- PubMed ID
- 41222242
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.